11 results
Event
Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation Biologics and Biosimilars: FDA Initiatives and Guidance, Approvals and Exclusivity, Patent Prosecution, Litigation
February 15, 2024
Webinar
Federal Circuit IP Blog
No Consequence for Board Issuing Final Written Decision Over 37 Months After Institution No Consequence for Board Issuing Final Written Decision Over 37 Months After Institution
December 7, 2023
Event
2023 ACC IP Symposium - Hot Topics in IP & Patent Litigation 2023 ACC IP Symposium - Hot Topics in IP & Patent Litigation
October 12, 2023
Virtual
Prosecution First Blog
Estoppel Halts Repeat Examination Estoppel Halts Repeat Examination
February 10, 2023
Podcasts
Director Review of Code200 v. Bright Data Director Review of Code200 v. Bright Data
November 17, 2022
Event
The Interplay between Inter Partes Review (IPR) Petition and Ex Parte Reexamination (XPR) The Interplay between Inter Partes Review (IPR) Petition and Ex Parte Reexamination (XPR)
August 24, 2022
Webinar
Federal Circuit IP Blog
Ex Parte Reexamination Scheme Did Not Preclude Review of Director’s Decision to Vacate Reexamination Proceedings Based on IPR Estoppel Ex Parte Reexamination Scheme Did Not Preclude Review of Director’s Decision to Vacate Reexamination Proceedings Based on IPR Estoppel
March 14, 2022
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.